AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15172704 — intervention group
Group type: EXPERIMENTAL
Intervention: Active impedance threshold device (ITD)
Number of subjects: 400
Study 15172704 — intervention group
Group type: COMPARATOR
Intervention: Sham valve
Number of subjects: 400
Study 10970701 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vaccination with several doses of Hib vaccine starting at three months
Number of subjects: 114000
Study 10970701 — intervention group
Group type: COMPARATOR
Intervention: Late vaccination with a single dose of Hib vaccine at two years
Number of subjects: 114000
Study 8874564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (80 micrograms.kg-1.min-1)
Number of subjects: 32
Study 8874564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1394219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (FCE 24304) 25 mg
Number of subjects: 29
Study 1394219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (FCE 24304) 50 mg
Number of subjects: 29
Study 1394219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (FCE 24304) 200 mg
Number of subjects: 29
Study 1394219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (FCE 24304) 400 mg
Number of subjects: 29
Study 1394219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (FCE 24304) 800 mg
Number of subjects: 29
Study 1394219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (FCE 24304) (all doses)
Number of subjects: 29
Study 3903778 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg naproxen
Number of subjects: 50
Study 3903778 — intervention group
Group type: COMPARATOR
Intervention: 20 mg piroxicam
Number of subjects: 50
Study 31870413 — intervention group
Group type: COMPARATOR
Intervention: Immediate prescription for antibiotics
Number of subjects: 45
Study 31870413 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate prescription for antibiotics plus a 7-day course of cranberry capsules
Number of subjects: 45
Study 31870413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules plus a delayed prescription for antibiotics
Number of subjects: 45
Study 29426699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-enriched enteral tube feeding from 3 h before until 6 h after surgery
Number of subjects: 265
Study 29426699 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no perioperative nutrition)
Number of subjects: 265
Study 26990685 — intervention group
Group type: EXPERIMENTAL
Intervention: Huddling programme (full-day retreat and after-work social networking services)
Number of subjects: 49
Study 26990685 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 49
Study 24937967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel supplementation (study group, n = 71)
Number of subjects: 149
Study 24937967 — intervention group
Group type: COMPARATOR
Intervention: No drug for luteal support (control group, n = 78)
Number of subjects: 149
Study 22320449 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with almotriptan
Number of subjects: 0
Study 22320449 — intervention group
Group type: COMPARATOR
Intervention: Non-early treatment
Number of subjects: 0
Study 20185669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPT) assessment at cervical zygapophysial joints
Number of subjects: 33
Study 20185669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPT) assessment with cutoff of 1 kPa
Number of subjects: 33
Study 20185669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPT) assessment with cutoff of 30 kPa
Number of subjects: 33
Study 20185669 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PPT between patients and pain-free subjects
Number of subjects: 33
Study 17950147 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose complex, 200 mg weekly for 5 weeks
Number of subjects: 40
Study 17950147 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 40
Study 16253504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (10 mg b.i.d.)
Number of subjects: 180
Study 16253504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular human chorionic gonadotrophin (hCG; 5000 IU every 4 days)
Number of subjects: 180
Study 16253504 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (controls)
Number of subjects: 180
Study 12003054 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon-2alpha
Number of subjects: 0
Study 9988780 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT oil (71 g)
Number of subjects: 20
Study 9988780 — intervention group
Group type: COMPARATOR
Intervention: Canola oil (71 g)
Number of subjects: 20
Study 9464324 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy for cervical cancer
Number of subjects: 0
Study 9464324 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy for tongue cancer
Number of subjects: 0
Study 9464324 — intervention group
Group type: COMPARATOR
Intervention: MDR brachytherapy for cervical cancer
Number of subjects: 0
Study 9464324 — intervention group
Group type: COMPARATOR
Intervention: LDR brachytherapy for tongue cancer
Number of subjects: 0
Study 1765893 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally based smoking-cessation program with methadone dose increase
Number of subjects: 0
Study 1765893 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 6416511 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 21
Study 6416511 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 21
Study 6416511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 21
Study 30838899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension control
Number of subjects: 10000
Study 30103776 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children for Teachers (ICC-T)
Number of subjects: 60
Study 30103776 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 60
Study 27318807 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 534
Study 27318807 — intervention group
Group type: COMPARATOR
Intervention: ICD-only
Number of subjects: 534
Study 24888732 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum intervention using a pedagogical communication strategy
Number of subjects: 300
Study 24888732 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 300
Study 23032060 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at three progressively higher rates (approximately 150, 350, and 700 pmol/liter) during hyperglycemia (glucose maintained at approximately 9 mmol/liter)
Number of subjects: 2
Study 23032060 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 2
Study 20547942 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical voriconazole
Number of subjects: 120
Study 20547942 — intervention group
Group type: COMPARATOR
Intervention: Scraping
Number of subjects: 120
Study 20547942 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical voriconazole (in patients with baseline BSCVA of 20/40 to 20/400)
Number of subjects: 120
Study 18580347 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg) intravenously over 10 minutes before induction of anesthesia
Number of subjects: 40
Study 18580347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 16286443 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1265
Study 16286443 — intervention group
Group type: COMPARATOR
Intervention: CMAI factor structure
Number of subjects: 1265
Study 12080437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Mediterranean diet and leisure time physical activity
Number of subjects: 848
Study 10743730 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ergometry or rapid walking) at 60-80% of maximal performance for 30 minutes once a day for 2 months
Number of subjects: 29
Study 7628178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoconazole
Number of subjects: 5
Study 1771224 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (75 mg)
Number of subjects: 36
Study 1771224 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg)
Number of subjects: 36
Study 1771224 — intervention group
Group type: COMPARATOR
Intervention: Lactate placebo
Number of subjects: 36
Study 6787141 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral hyperalimentation fluids
Number of subjects: 131
Study 6787141 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive blood cultures for yeast
Number of subjects: 131
Study 6787141 — intervention group
Group type: COMPARATOR
Intervention: No eye lesions
Number of subjects: 131
Study 30579806 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks added to rosuvastatin 10 mg/day
Number of subjects: 0
Study 30579806 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care arm (rosuvastatin 10 mg/day, with initiation and/or dose adjustment of non-statin lipid-lowering to achieve an LDL-C target of <70 mg/dL)
Number of subjects: 0
Study 28885317 — intervention group
Group type: COMPARATOR
Intervention: PLGA/HA/β-TCP
Number of subjects: 13
Study 28885317 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGA/HA/β-TCP with 2.0% simvastatin
Number of subjects: 13
Study 28885317 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM-C
Number of subjects: 13
Study 28885317 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (control)
Number of subjects: 13
Study 25834412 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency low-intensity pulsed magnetic field (LFLIPMF)
Number of subjects: 30
Study 25834412 — intervention group
Group type: COMPARATOR
Intervention: Circuit weight training (CWT)
Number of subjects: 30
Study 23670660 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice level training in a whole systems approach to self management support.
Number of subjects: 5599
Study 23670660 — intervention group
Group type: COMPARATOR
Intervention: Control practices (no specific intervention mentioned).
Number of subjects: 5599
Study 21419745 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg/d MK-0736
Number of subjects: 54
Study 21419745 — intervention group
Group type: COMPARATOR
Intervention: MK-0916
Number of subjects: 54
Study 21419745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19263464 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antidepressant groups
Number of subjects: 8385
Study 19263464 — intervention group
Group type: COMPARATOR
Intervention: Placebo groups
Number of subjects: 8385
Study 19263464 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mean Hamilton Depression Rating Scale (HDRS)
Number of subjects: 8385
Study 19263464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size
Number of subjects: 8385
Study 19263464 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment allocation
Number of subjects: 8385
Study 19263464 — intervention group
Group type: EXPERIMENTAL
Intervention: Study duration
Number of subjects: 8385
Study 19263464 — intervention group
Group type: EXPERIMENTAL
Intervention: Study location (USA)
Number of subjects: 8385
Study 17723086 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0
Study 17723086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilatory antihypertensives (renin-angiotensin-aldosterone system inhibitors and calcium channel blockers)
Number of subjects: 0
Study 17723086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15114089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205
Study 15114089 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine-ME
Number of subjects: 205
Study 11405308 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced visual acuity through partial occlusion filters
Number of subjects: 0
Study 11405308 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced auditory acuity through headphone-shaped noise protectors
Number of subjects: 0
Study 11405308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both visual and auditory acuity reductions
Number of subjects: 0
Study 11405308 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (not explicitly defined)
Number of subjects: 0
Study 9885116 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII (2500 units postoperatively)
Number of subjects: 22
Study 9885116 — intervention group
Group type: COMPARATOR
Intervention: Control (no Factor XIII administration)
Number of subjects: 22
Study 7930743 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose artesunate (4 mg/kg) plus mefloquine (25 mg of base/kg)
Number of subjects: 652
Study 7930743 — intervention group
Group type: EXPERIMENTAL
Intervention: Three days of artesunate (total dose, 10 mg/kg) plus mefloquine (25 mg/kg)
Number of subjects: 652
Study 2124724 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-micrograms misoprostol tablets twice daily
Number of subjects: 137
Study 2124724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 426986 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 0.5‐6.0 microgram kg‐1 min‐1
Number of subjects: 0
Study 426986 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.25 mg kg‐1
Number of subjects: 0
Study 31164153 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel-unloading orthosis (Settner shoe)
Number of subjects: 0
Study 31164153 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without the orthosis
Number of subjects: 0
Study 28292202 — intervention group
Group type: EXPERIMENTAL
Intervention: Proso millet products (couscous, biscuit, extruded snack, porridge)
Number of subjects: 12
Study 28292202 — intervention group
Group type: COMPARATOR
Intervention: Corn products (couscous, biscuit, extruded snack, porridge)
Number of subjects: 12
Study 25872390 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (nepafenac)
Number of subjects: 80
Study 25872390 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIDs (dexamethasone)
Number of subjects: 80
Study 25872390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (nepafenac and dexamethasone)
Number of subjects: 80
Study 25872390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative therapy)
Number of subjects: 80
Study 23963586 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to rest
Number of subjects: 52650
Study 23963586 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing others with disabling LBP
Number of subjects: 52650
Study 23963586 — intervention group
Group type: EXPERIMENTAL
Intervention: History of chronic LBP
Number of subjects: 52650
Study 23963586 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiating pain below the knee
Number of subjects: 52650
Study 23963586 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers' compensation
Number of subjects: 52650
Study 23963586 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 52650
Study 23963586 — intervention group
Group type: EXPERIMENTAL
Intervention: LBP attributed to sports
Number of subjects: 52650
Study 21241352 — intervention group
Group type: EXPERIMENTAL
Intervention: DCF100C 1.0%
Number of subjects: 20
Study 21241352 — intervention group
Group type: EXPERIMENTAL
Intervention: DCF100C 2.5%
Number of subjects: 20
Study 21241352 — intervention group
Group type: EXPERIMENTAL
Intervention: DCF100C 1.0% with menthol and eucalyptus oil
Number of subjects: 20
Study 21241352 — intervention group
Group type: EXPERIMENTAL
Intervention: DCF100C 2.5% without sensory excipients
Number of subjects: 20
Study 21241352 — intervention group
Group type: COMPARATOR
Intervention: Voltaren Emulgel 1.0%
Number of subjects: 20
Study 19827650 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin-eluting stents
Number of subjects: 26
Study 19827650 — intervention group
Group type: COMPARATOR
Intervention: Control (group 2)
Number of subjects: 26
Study 16949661 — intervention group
Group type: EXPERIMENTAL
Intervention: Permaquick applied with the stiff micro‐hybrid composite Amelogen Hybrid (PMQ/A‐Hy, Ultradent)
Number of subjects: 71
Study 16949661 — intervention group
Group type: EXPERIMENTAL
Intervention: Permaquick applied with the more flexible micro‐filled composite Amelogen Microfill (PMQ/A‐Mi, Ultradent)
Number of subjects: 71
Study 16949661 — intervention group
Group type: COMPARATOR
Intervention: Optibond FL applied with the micro‐hybrid composite Prodigy (O‐FL/Pro, Kerr)
Number of subjects: 71
Study 15497671 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Ecrox) 25 mg rofecoxib tablet
Number of subjects: 24
Study 15497671 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (originator product) 25 mg rofecoxib tablet
Number of subjects: 24
Study 11442183 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded instructions in patients' native language
Number of subjects: 60
Study 11442183 — intervention group
Group type: COMPARATOR
Intervention: Interpreter‐assisted instructions
Number of subjects: 60
Study 9917607 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced posterior soft tissue repair after total hip replacement
Number of subjects: 679
Study 9917607 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior approach to total hip replacement (before enhanced closure)
Number of subjects: 679
Study 8113775 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 59
Study 8113775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 3186379 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (n = 8)
Number of subjects: 40
Study 3186379 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (n = 5)
Number of subjects: 40
Study 3186379 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation and Conventional ventilation
Number of subjects: 40
Study 3186379 — intervention group
Group type: EXPERIMENTAL
Intervention: Not bronchoscoped infants
Number of subjects: 40
Study 1103765 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 42
Study 1103765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31164160 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year multimodal intervention (diet, exercise, cognitive training, vascular risk monitoring)
Number of subjects: 1260
Study 31164160 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year multimodal intervention
Number of subjects: 1260
Study 31164160 — intervention group
Group type: COMPARATOR
Intervention: Control (general health advice)
Number of subjects: 1260
Study 28418808 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched margarine and rapeseed oil (MR)
Number of subjects: 76
Study 28418808 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (R)
Number of subjects: 76
Study 28418808 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched margarine (M)
Number of subjects: 76
Study 28418808 — intervention group
Group type: COMPARATOR
Intervention: Olive oil control diet (O)
Number of subjects: 76
Study 28418808 — intervention group
Group type: EXPERIMENTAL
Intervention: MR group
Number of subjects: 76
Study 28418808 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid and trans FA concentrations
Number of subjects: 76
Study 26252316 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RC)
Number of subjects: 80
Study 26252316 — intervention group
Group type: COMPARATOR
Intervention: Control (blood pressure cuff inflated to 25 mm Hg)
Number of subjects: 80
Study 23902673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin protein isolate (LPI) 25 g/d
Number of subjects: 33
Study 23902673 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 33
Study 23902673 — intervention group
Group type: COMPARATOR
Intervention: Lupin protein isolate (LPI) and Milk protein isolate (MPI)
Number of subjects: 33
Study 21715698 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy (3 months)
Number of subjects: 18
Study 21715698 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute L-ascorbate alone
Number of subjects: 18
Study 21715698 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ascorbate combined with arginase inhibition
Number of subjects: 18
Study 21715698 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline in NC)
Number of subjects: 18
Study 21715698 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline in HC)
Number of subjects: 18
Study 21715698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate alone post-atorvastatin
Number of subjects: 18
Study 21715698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate combined with arginase inhibition post-atorvastatin
Number of subjects: 18
Study 19210493 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 1392
Study 19210493 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 1392
Study 19210493 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg
Number of subjects: 1392
Study 16703434 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (2 mg/kg of bupivacaine in 200 ml of normal saline before creation of pneumoperitoneum)
Number of subjects: 120
Study 16703434 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (2 mg/kg of bupivacaine in 200 ml of normal saline after creation of pneumoperitoneum)
Number of subjects: 120
Study 16703434 — intervention group
Group type: COMPARATOR
Intervention: Group C (200 ml of normal saline before creation of pneumoperitoneum)
Number of subjects: 120
Study 16703434 — intervention group
Group type: COMPARATOR
Intervention: Group D (200 ml of normal saline after creation of pneumoperitoneum)
Number of subjects: 120
Study 16703434 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 120
Study 16703434 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 120
Study 16703434 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 120
Study 16703434 — intervention group
Group type: COMPARATOR
Intervention: Group D
Number of subjects: 120